Meet Our Team
We're a team of scientists, clinicians, and communicators working to close the gap between genetic testing and effective treatment, so a diagnosis leads to real options for rare disease patients.
Leadership & Team
Advisors & Consultants
Frederick Roth, Ph.D.
Interns
Andy Negrut
Meet Our Team
We're a team of scientists, clinicians, and communicators working to close the gap between genetic testing and effective treatment, so a diagnosis leads to real options for rare disease patients.
Leadership & Team
Nicholas is a biophysicist with expertise in computational and experimental methods. His past academic work focused on several areas of protein biophysics including molecular mechanisms of disease, membrane proteins, misfolding and aggregation, and evolution and design. He holds a Ph.D. in Physics from Rice University, was a Postdoc at Aarhus University, and is a visiting scientist at the Center for Theoretical Biological Physics. As CEO and co-founder of Constantiam Biosciences.
nick@constantiambio.comDaniel is a biochemist with broad expertise in the biomedical sciences, including gene therapies, gene editing, RNA biology, and protein folding. He holds a Ph.D. in Chemistry from the University of California, Berkeley, and was a Damon Runyon Cancer Research fellow at The Johns Hopkins University School of Medicine. As CSO and co-founder of Constantiam Biosciences, Daniel is focused on developing core technologies to advance genomic medicine.
daniel@constantiambio.comAs a scientist by training, he has held multiple technology transfer and business development roles in academic, venture, incubator and large corporation settings. He holds a Ph.D. in Nutritional Biochemistry from the University of Minnesota-Twin Cities, and was doctoral dissertation and Larry L. Hillblom Foundation fellow. He is also a certified licensing professional (CLP) and has closed over $90M worth of licenses and service contracts.
norman@constantiambio.com
Ethan is a Master's-level scientist with four years of industry experience in virus and Cas9-related virus-like particle (VLP) production, screening, and qualification. Ethan has led a collaborative vector core unit and driven digital, data, and technology (DD&T) development initiatives. Ethan's academic background includes two years of research in gene editing, with a thesis on CRISPR-Cas9 knock-in mutations in cancer, including BRCA1 characterization.
ethan@constantiambio.comZainab is a Marketing and Communications Strategist at Constantiam Biosciences. She holds a Bachelor's degree in Microbiology and Molecular Genetics and a Master's degree in Public Health. She is also a Meta Certified Creative Strategist with a Digital Health certification from Harvard Business School.
zainab@constantiambio.comAdvisors & Consultants
Frederick Roth, Ph.D.
Frederick (Fritz) Roth is Professor and Chair of Computational and Systems Biology at the University of Pittsburgh School of Medicine, and a pioneer in massively-multiplexed functional assays and computational variant effect predictors. He works directly with the co-founders on technology, research goals, and product direction.
frederick@constantiambio.comEric is an experienced life sciences senior executive, beginning at Procter & Gamble and Boston Consulting Group before serving as CEO for several biomedical companies, including Targeted Cell Therapies, Abazyme, Lumos Catheter Systems, and Follica Biosciences.
eric@constantiambio.comVictoria (Vicki) Parikh directs the Center for Inherited Cardiovascular Disease and is an Assistant Professor at Stanford, splitting her time between clinic and lab. She works with the co-founders to ensure maximum positive clinical impact.
victoria@constantiambio.comJeanne is a trained Clinical Genomic Scientist and experienced Product Manager who has led product development and technology integration for multiple genetic testing companies, ensuring the roadmap aligns with industry needs.
jeanne@constantiambio.comEmil is a data scientist and engineering leader who has built four teams from the ground up across multiple industries. He holds a B.S. in Physics and an M.S. in Electrical Engineering from Aarhus University.
emil@constantiambio.comFrank is Managing Director at FHF Ventures, holding an MBA from the University of Chicago. He brings decades of experience selling high-value data assets in a B2B setting and advising executive teams.
frank@constantiambio.comBrian is a board-certified physician and Assistant Director of UW Medicine Genetics and Solid Tumor Informatics at UW Laboratory Medicine, specializing in genetic testing for hereditary cancer risk and rare variant classification.
brian@constantiambio.comInterns
Andy Negrut
Andy is a student majoring in computer science with a primary interest in machine learning and AI, working on Constantiam's systems for understanding genetic variants. He is currently pursuing a degree at Rice University.
